AKEBIA THERAPEUTICS, INC. Deferred Tax Liabilities, Gross
AKEBIA THERAPEUTICS, INC. (AKBA) had Deferred Tax Liabilities, Gross of $1.55 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-26
- 2025-12-31: Deferred Tax Liabilities, Gross $1.55M.
- 2024-12-31: Deferred Tax Liabilities, Gross $3.38M.
- 2023-12-31: Deferred Tax Liabilities, Gross $11.64M.
- 2022-12-31: Deferred Tax Liabilities, Gross $23.49M.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $1.55M 10-K · filed 2026-02-26 |
| 2024-12-31 | $3.38M 10-K · filed 2026-02-26 |
| 2023-12-31 | $11.64M 10-K · filed 2025-03-13 |
| 2022-12-31 | $23.49M 10-K · filed 2024-03-14 |
| 2021-12-31 | $34.37M 10-K/A · filed 2023-08-28 |
| 2020-12-31 | $49.35M 10-K · filed 2022-03-01 |
| 2019-12-31 | $109.35M 10-K · filed 2021-02-25 |
| 2018-12-31 | $119.41M 10-K · filed 2020-03-12 |
| 2017-12-31 | $181.00K 10-K · filed 2019-03-26 |
| 2016-12-31 | $6.00K 10-K · filed 2018-03-12 |
| 2015-12-31 | $2.00K 10-K · filed 2017-03-06 |
| 2013-12-31 | $108.48K 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |